Suppressive effects of antimycotics on thymic stromal lymphopoietin production in human keratinocytes

Journal of Dermatological Science

Volumn 71, Issue 3, 2013, Pages 174-183

  Hau, Carren S ^a   Kanda, Naoko ^a   Watanabe, Shinichi ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

15 Deoxy 12,14 PGJ2; Antimycotic; Atopic dermatitis; Keratinocyte; NF B; Thymic stromal lymphopoietin

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; AMOROLFINE; ANTIFUNGAL AGENT; BUTENAFINE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; ITRACONAZOLE; KETOCONAZOLE; LIPOCALIN; LULICONAZOLE; MESSENGER RNA; POLYINOSINIC POLYCYTIDYLIC ACID; PROSTAGLANDIN D SYNTHASE; TERBINAFINE; THROMBOXANE B2; THYMIC STROMAL LYMPHOPOIETIN;

ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; KERATINOCYTE; MALE; NEWBORN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

15-DEOXY-Δ-(12,14)-PGJ(2); 15-DEOXY-Δ-(12,14)-PROSTAGLANDIN J(2); 15D-PGJ(2); AD; ANALYSIS OF VARIANCE; ANOVA; ANTIMYCOTIC; ATOPIC DERMATITIS; CHEMOATTRACTANT RECEPTOR-HOMOLOGOUS MOLECULE EXPRESSED ON TH2 CELLS; CRTH2; D PROSTANOID RECEPTOR; DIMETHYLSULFOXIDE; DMSO; DP; GAPDH; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE; HPGDS; IKK; INHIBITORY ΚB; IΚB; IΚB KINASE; KBM; KERATINOCYTE; KERATINOCYTE BASAL MEDIUM; LIPOCALIN-TYPE PROSTAGLANDIN D SYNTHASE; LPGDS; NEMO; NF-ΚB; NF-ΚB ESSENTIAL MODIFIER; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR Γ; PG; POLY I:C; POLYINOSINIC-POLYCYTIDYLIC ACID; PPARΓ; PROSTAGLANDIN; RECEPTOR INTERACTING PROTEIN 1; RIP1; TAK1; TGF-Β ACTIVATED KINASE 1; THROMBOXANE A(2); THROMBOXANE A(2) SYNTHASE; THYMIC STROMAL LYMPHOPOIETIN; TNF RECEPTOR; TNF RECEPTOR-ASSOCIATED DEATH DOMAIN; TNF RECEPTOR-ASSOCIATED FACTOR; TNFR; TOLL/IL-1 RECEPTOR DOMAIN-CONTAINING ADAPTOR INDUCING IFN-Β; TRADD; TRAF; TRIF; TSLP; TXA(2); TXAS;

ANTIFUNGAL AGENTS; CELLS, CULTURED; CYTOKINES; DERMATITIS, ATOPIC; HUMANS; INTERLEUKIN-4; KERATINOCYTES; NF-KAPPA B; POLY I-C; PROSTAGLANDIN D2; RECOMBINANT PROTEINS; RNA, MESSENGER;

EID: 84881558331     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2013.04.023     Document Type: Article

References (38)

1. Ziegler S.F., Liu Y.J. Thymic stromal lymphopoietin in normal and pathogenic T cell development and function. Nat Immunol 2006, 7:709-714.
2. Soumelis V., Reche P.A., Kanzler H., Yuan W., Edward G., Homey B., et al. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 2002, 3:673-680.
3. Wang Y.H., Ito T., Wang Y.H., Homey B., Watanabe N., Martin R., et al. Maintenance and polarization of human TH2 central memory T cells by thymic stromal lymphopoietin-activated dendritic cells. Immunity 2006, 24:827-838.
4. Sano Y., Masuda K., Tamagawa-Mineoka R., Matsunaka H., Murakami Y., Yamashita R., et al. Thymic stromal lymphopoietin expression is increased in the horny layer of patients with atopic dermatitis. Clin Exp Immunol 2013, 171:330-337.
5. Vu A.T., Chen X., Xie Y., Kamijo S., Ushio H., Kawasaki J., et al. Extracellular double-stranded RNA induces TSLP via an endosomal acidification- and NF-κB-dependent pathway in human keratinocytes. J Invest Dermatol 2011, 131:2205-2212.
6. Vu A.T., Baba T., Chen X., Le T.A., Kinoshita H., Xie Y., et al. Staphylococcus aureus membrane and diacylated lipopeptide induce thymic stromal lymphopoietin in keratinocytes through the Toll-like receptor 2-Toll-like receptor 6 pathway. J Allergy Clin Immunol 2010, 126:985-993.
7. Takai T. TSLP expression: cellular sources, triggers, and regulatory mechanisms. Allergol Int 2012, 61:3-17.
8. Ikezawa Z., Kondo M., Okajima M., Nishimura Y., Kono M. Clinical usefulness of oral itraconazole, an antimycotic drug, for refractory atopic dermatitis. Eur J Dermatol 2004, 14:400-406.
9. Nikkels A.F., Piérard G.E. Framing the future of antifungals in atopic dermatitis. Dermatology 2003, 206:398-400.
10. Darabi K., Hostetler S.G., Bechtel M.A., Zirwas M. The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol 2009, 60:125-136.
11. Squire R.A., Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatol Treat 2002, 13:51-60.
12. Kanda N., Watanabe S. Suppressive effects of antimycotics on tumor necrosis factor-α-induced CCL27, CCL2, and CCL5 production in human keratinocytes. Biochem Pharmacol 2006, 72:463-473.
13. Kanda N., Watanabe S. Ketoconazole suppresses interleukin-4 plus anti-CD40-induced IgE class switching in surface IgE negative B cells from patients with atopic dermatitis. J Invest Dermatol 2002, 119:590-599.
14. Kanda N., Kano R., Ishikawa T., Watanabe S. The antimycotic drugs itraconazole and terbinafine hydrochloride induce the production of human β-defensin-3 in human keratinocytes. Immunobiology 2011, 216:497-504.
15. 2: the anti-inflammatory prostaglandin?. Clin Immunol 2005, 114:100-109.
16. Herlong J.L., Scott T.R. Positioning prostanoids of the D and J series in the immunopathogenic scheme. Immunol Lett 2006, 102:121-131.
17. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci USA 2000, 97:4844-4849.
18. Koga H., Nanjoh Y., Makimura K., Tsuboi R. In vitro antifungal activities of luliconazole, a new topical imidazole. Med Mycol 2009, 47:640-647.
19. Xie Y., Takai T., Chen X., Okumura K., Ogawa H. Long TSLP transcript expression and release of TSLP induced by TLR ligands and cytokines in human keratinocytes. J Dermatol Sci 2012, 66:233-237.
20. 2. Proc Natl Acad Sci USA 2007, 104:20979-20984.
21. 2 synthase in the control of delayed type hypersensitivity. Proc Natl Acad Sci USA 2006, 103:5179-5184.
22. Lin T.H., Tang C.H., Wu K., Fong Y.C., Yang R.S., Fu W.M. 15-Deoxy-δ(12,14) -prostaglandin-J2 and ciglitazone inhibit TNF-α-induced matrix metalloproteinase 13 production via the antagonism of NF-κB activation in human synovial fibroblasts. J Cell Physiol 2011, 226:3242-3250.
23. Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Annu Rev Pharmacol Toxicol 2005, 45:51-88.
24. Tolman E.L., Fuller B.L. Inhibition of thromboxane synthesis in guinea pig lung and human platelets by clotrimazole and other imidazole antifungals. Biochem Pharmacol 1983, 32:3488-3490.
25. 2 synthase in macrophages is mediated through the activation of peroxisome proliferator-activated receptor (PPAR) γ. J Biol Chem 2011, 286:27471-27482.
26. Scheidereit C. IκB kinase complexes: gateways to NF-κB activation and transcription. Oncogene 2006, 25:6685-6705.
27. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11:373-384.
28. Bhattacharjee R., Xiang W., Wang Y., Zhang X., Billiar T.R. cAMP prevents TNF-induced apoptosis through inhibiting DISC complex formation in rat hepatocytes. Biochem Biophys Res Commun 2012, 423:85-90.
29. Guevara Patiño J.A., Ivanov V.N., Lacy E., Elkon K.B., Marino M.W., Nikolic-Zugić J. TNF-α is the critical mediator of the cyclic AMP-induced apoptosis of CD8+4+ double-positive thymocytes. J Immunol 2000, 164:1689-1694.
30. Hsu P.Y., Tsai A.L., Kulmacz R.J., Wang L.H. Expression, purification, and spectroscopic characterization of human thromboxane synthase. J Biol Chem 1999, 274:762-769.
31. Wang L.H., Tsai A.L., Hsu P.Y. Substrate binding is the rate-limiting step in thromboxane synthase catalysis. J Biol Chem 2001, 276:14737-14743.
32. Matsuura K., Yoshioka S., Tosha T., Hori H., Ishimori K., Kitagawa T., et al. Structural diversities of active site in clinical azole-bound forms between sterol 14alpha-demethylases (CYP51s) from human and Mycobacterium tuberculosis. J Biol Chem 2005, 280:9088-9096.
33. Steel H.C., Tintinger G.R., Anderson R. Comparison of the anti-inflammatory activities of imidazole antimycotics in relation to molecular structure. Chem Biol Drug Des 2008, 72:225-228.
34. Faergemann J., Zehender H., Jones T., Maibach I. Terbinafine levels in serum, stratum corneum, dermis-epidermis (without stratum corneum), hair, sebum and eccrine sweat. Acta Derm Venereol 1991, 71:322-326.
35. H17-related cytokines. J Allergy Clin Immunol 2012, 130:233-240.
36. Wong A.W., Hon E.K., Zee B. Is topical antimycotic treatment useful as adjuvant therapy for flexural atopic dermatitis: randomized, double-blind, controlled trial using one side of the elbow or knee as a control. Int J Dermatol 2008, 47:187-191.
37. Kabashima-Kubo R., Nakamura M., Sakabe J., Sugita K., Hino R., Mori T., et al. A group of atopic dermatitis without IgE elevation or barrier impairment shows a high Th1 frequency: possible immunological state of the intrinsic type. J Dermatol Sci 2012, 67:37-43.
38. Ishibashi Y., Sugita T., Nishikawa A. Cytokine secretion profile of human keratinocytes exposed to Malassezia yeasts. FEMS Immunol Med Microbiol 2006, 48:400-409.